Table 1

Reduction in the retail price (excl. VAT) of adalimumab, etanercept, originator infliximab and biosimilar infliximab since their introduction in France

BiotherapyVolume, presentationEffective date of the new retail priceRetail price (excl. VAT, in €)Reduction in retail price between 2012 and 2015 (percent decrease)
Adalimumab
(Humira)
40 mg
syringe or pen
513.45
15 Sep 2010462.11
1 Feb 2013443.62
1 Aug 2013417.01−9.76%
Etanercept
(Enbrel)
25 mg
syringe
126.08
15 Sep 2010113.47
24 Apr 2013109.50
1 Mar 2014105.67−6.88%
50 mg
syringe or pen
252.16
15 Sep 2010226.95
24 Apr 2013219.00
1 Mar 2014211.34−6.88%
Originator infliximab
(Remicade)
100 mg
vial
561.00
1 Sep 2009536.28
1 Oct 2010509.47
1 Jun 2011482.67
1 Nov 2014434.40−10.0%
Biosimilar infliximab
(Inflectra)
100 mg
vial
27 Jan 2015434.40
  • excl. VAT, exclusive of value added tax.